Global Companion Diagnostics Market- Technologies, Market share and Industry Forecast to 2024

Global Companion Diagnostics Market- Technologies, Market share and Industry Forecast to 2024


  • Products Id :- HAD-8431117
  • |
  • Pages: 240
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

The global companion diagnostics market is expected to grow at a CAGR of over 20.1% during the period of 2017-2024. Companion diagnostic tests are used for collecting patient information, dosing requirement, and susceptibility regarding the side effects of any particular drug. Companion diagnostics tests are also known as pharmacogenetic tests. While many drug labels provide guidance on pharmacogenetic testing, certain drugs specifically cancer drugs, require patients to receive a diagnostic test, as the efficacy of these drugs is limited to those with a particular genotype. Major driving forces of companion diagnostics are improved regulatory guidelines, rising cancer incidence across the globe, need for targeted therapies, and increasing collaborations and partnerships for test development. The companion diagnostics market is fastest growing segments of the IVD and clinical lab services markets. United States, over half of all FDA approvals for companion diagnostics have occurred since 2010. The closely associated pharmacodiagnostics IVD market is expected to grow annually by over 20%. Approval of CDX- assisted therapies, and high growth of market opened for laboratory tests and IVD products. Global companion diagnostics is facing challenges as prolonged development time of companion diagnostics, increasing duration of the approval, in spite of all challenges there are huge opportunities as process increasing new indication areas, increasing demand for next-generation sequencing, increasing number of clinical trials which will leverage the market of data fabric.?

The global companion diagnostics market is segmented on the basis of product & services, indication, technology and end user. Indication segment consist of oncology, cardiovascular conditions, central nervous system indications, inflammation and virology segment. Oncology is dominating the indication segment. Technology market is segmented as Immunohistochemistry and Molecular diagnostics etc. Molecular diagnostics is the fastest growing and highest revenue generator product & service segment consist of assay kits, reagents, and software & services. End user segment of market is differentiate into pharmaceutical & biopharmaceutical companies, reference laboratories, and other end users. The pharmaceutical and biopharmaceutical companies segment is dominating the market during the forecasted period.

Geographically North America hold the largest share in companion diagnostics market, due to the high technological advancements in the region. Asia Pacific market is expected to grow at the highest CAGR between 2017 and 2024. The primary forces which are driving growth of the market are the growing prevalence diseases like cancer and neurology diseases, also increasing number of hospitals and diagnostics laboratories are creating huge opportunity which is driving the growth of the companion diagnostics market.

The growth in global companion diagnostics market is also influenced by the presence of major players such Qiagen n.v. (Netherland), Thermo Fisher Scientific Inc. (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Genomic Health, Inc. (US) and other. Collaborations and partnership etc. are some crucial strategies adopted by the major players to gain competitive advantage.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1. INTRODUCTION

1.1. EXECUTIVE SUMMARY

1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

2.1. GLOBAL COMPANION DIAGNOSTIC MARKET: EVOLUTION & TRANSITION

2.2. MARKET DEFINITION & SCOPE

2.3. INDUSTRY STRUCTURE

2.4. REGULATORY FRAMEWORK

2.5. TOTAL MARKET ANALYSIS

2.5.1. TOP 5 FINDINGS

2.5.2. TOP 5 OPPORTUNITY MARKETS

2.5.3. TOP 5 COMPANIES

2.5.4. TOP 3 COMPETITIVE STRATEGIES

2.6. ESTIMATION ANALYSIS

2.7. STRATEGIC ANALYSIS

2.7.1. INVESTMENT VS. ADOPTION MODEL

2.7.2. 360-DEGREE INDUSTRY ANALYSIS

2.7.3. PORTERS 5 FORCE MODEL

2.7.4. SEE-SAW ANALYSIS

2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA

2.8. COMPETITIVE ANALYSIS

2.8.1. KEY STRATEGIES & ANALYSIS

2.8.2. MARKET SHARE ANALYSIS AND TOP MARKET ANALYSIS

2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS

2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS

2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS

2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

3.1. MARKET DRIVERS

3.1.1. IMPROVEMENTS IN REGULATORY GUIDELINES

3.1.2. GROWING NEED FOR TARGETED THERAPIES

3.1.3. RISING CANCER INCIDENCE ACROSS THE GLOBE

3.1.4. INCREASING PARTNERSHIPS AND COLLABORATIONS FOR COMPANION DIAGNOSTICS TEST DEVELOPMENT

3.2. MARKET RESTRAINTS

3.2.1. UNFAVORABLE REIMBURSEMENT SCENARIO

3.2.2. INTELLECTUAL PROPERTY RIGHTS PROTECTION ISSUES

3.3. MARKET OPPORTUNITIES

3.3.1. INCREASING NEW INDICATION AREAS

3.3.2. INCREASING DEMAND FOR NEXT-GENERATION SEQUENCING

3.3.3. INCREASING NUMBER OF CLINICAL TRIALS

3.4. MARKET CHALLENGES

3.4.1. PROLONGED DEVELOPMENT TIME OF COMPANION DIAGNOSTICS

3.4.2. INCREASING DURATION OF THE APPROVAL PROCESS

4. GLOBAL COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE

4.1. MARKET DEFINITION AND SCOPE

4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.4. OPPORTUNITY MATRIX

4.5. MARKET SEGMENTATION

4.5.1. GLOBAL ASSAY KITS AND REAGENTS MARKET

4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

4.5.1.3. KEY PLAYERS & KEY PRODUCTS

4.5.1.4. KEY CONCLUSIONS

4.5.2. GLOBAL SOFTWARE AND SERVICE MARKET

4.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS

4.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

4.5.2.3. KEY PLAYERS & KEY PRODUCTS

4.5.2.4. KEY CONCLUSIONS

5. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY

5.1. MARKET DEFINITION AND SCOPE

5.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

5.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

5.4. OPPORTUNITY MATRIX

5.5. MARKET SEGMENTATION

5.5.1. GLOBAL IN SITU HYBRIDIZATION MARKET

5.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

5.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

5.5.1.3. KEY PLAYERS & KEY PRODUCTS

5.5.1.4. KEY CONCLUSIONS

5.5.2. GLOBAL POLYMERASE CHAIN REACTION MARKET

5.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS

5.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

5.5.2.3. KEY PLAYERS & KEY PRODUCTS

5.5.2.4. KEY CONCLUSIONS

5.5.3. GLOBAL IMMUNOHISTOCHEMISTRY MARKET

5.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS

5.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

5.5.3.3. KEY PLAYERS & KEY PRODUCTS

5.5.3.4. KEY CONCLUSIONS

5.5.4. GLOBAL NEXT GENERATION SEQUENCING MARKET

5.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS

5.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

5.5.4.3. KEY PLAYERS & KEY PRODUCTS

5.5.4.4. KEY CONCLUSIONS

5.5.5. GLOBAL OTHER TECHNOLOGIES MARKET

5.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS

5.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

5.5.5.3. KEY PLAYERS & KEY PRODUCTS

5.5.5.4. KEY CONCLUSIONS

6. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATION

6.1. MARKET DEFINITION AND SCOPE

6.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

6.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

6.4. OPPORTUNITY MATRIX

6.5. MARKET SEGMENTATION

6.5.1. GLOBAL ONCOLOGY MARKET

6.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

6.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

6.5.1.3. KEY PLAYERS & KEY PRODUCTS

6.5.1.4. KEY CONCLUSIONS

6.5.2. GLOBAL NEUROLOGY MARKET

6.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS

6.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

6.5.2.3. KEY PLAYERS & KEY PRODUCTS

6.5.2.4. KEY CONCLUSIONS

6.5.3. GLOBAL INFECTIOUS DISEASES MARKET

6.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS

6.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

6.5.3.3. KEY PLAYERS & KEY PRODUCTS

6.5.3.4. KEY CONCLUSIONS

6.5.4. GLOBAL OTHER INDICATIONS MARKET

6.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS

6.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

6.5.4.3. KEY PLAYERS & KEY PRODUCTS

6.5.4.4. KEY CONCLUSIONS

7. GLOBAL COMPANION DIAGNOSTIC MARKET, BY END USER

7.1. MARKET DEFINITION AND SCOPE

7.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

7.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

7.4. OPPORTUNITY MATRIX

7.5. MARKET SEGMENTATION

7.5.1. GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET

7.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS

7.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

7.5.1.3. KEY PLAYERS & KEY PRODUCTS

7.5.1.4. KEY CONCLUSIONS

7.5.2. GLOBAL REFERENCE LABORATORIES MARKET

7.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS

7.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

7.5.2.3. KEY PLAYERS & KEY PRODUCTS

7.5.2.4. KEY CONCLUSION

7.5.3. GLOBAL OTHER END USER MARKET

7.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS

7.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

7.5.3.3. KEY PLAYERS & KEY PRODUCTS

7.5.3.4. KEY CONCLUSION

8. COMPETITIVE LANDSCAPE

8.1. KEY STRATEGIES

8.1.1. LIST OF MERGERS AND ACQUISITION

8.1.2. LIST OF JOINT VENTURES

8.1.3. LIST OF PRODUCT LAUNCHES

8.1.4. LIST OF PARTNERSHIPS

9. GEOGRAPHICAL ANALYSIS

9.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

9.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

9.3. OPPORTUNITY MATRIX

9.4. GLOBAL COMPANION DIAGNOSTIC MARKET BY REGION 2015-2024 (USD MILLION)

9.4.1. NORTH AMERICA

9.4.1.1. INDUSTRY ANALYSIS 2015-2024 (USD MILLION)

9.4.1.2. TOP COUNTRY ANALYSIS

9.4.1.2.1. U.S.

9.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.1.2.1.2. KEY PLAYERS & KEY PRODUCTS

9.4.1.2.1.3. KEY CONCLUSIONS

9.4.1.2.2. CANADA

9.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.1.2.2.2. KEY PLAYERS & KEY PRODUCTS

9.4.1.2.2.3. KEY CONCLUSIONS

9.4.2. EUROPE

9.4.2.1. INDUSTRY ANALYSIS 2015-2024 (USD MILLION)

9.4.2.2. TOP COUNTRY ANALYSIS

9.4.2.2.1. UK

9.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.2.2.1.2. KEY PLAYERS & KEY PRODUCTS

9.4.2.2.1.3. KEY CONCLUSIONS

9.4.2.2.2. FRANCE

9.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.2.2.2.2. KEY PLAYERS & KEY PRODUCTS

9.4.2.2.2.3. KEY CONCLUSIONS

9.4.2.2.3. GERMANY

9.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.2.2.3.2. KEY PLAYERS & KEY PRODUCTS

9.4.2.2.3.3. KEY CONCLUSIONS

9.4.2.2.4. SPAIN

9.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.2.2.4.2. KEY PLAYERS & KEY PRODUCTS

9.4.2.2.4.3. KEY CONCLUSIONS

9.4.2.2.5. REST OF EUROPE

9.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.2.2.5.2. KEY PLAYERS & KEY PRODUCTS

9.4.2.2.5.3. KEY CONCLUSIONS

9.4.3. ASIA PACIFIC

9.4.3.1. INDUSTRY ANALYSIS 2015-2024 (USD MILLION)

9.4.3.2. TOP COUNTRY ANALYSIS

9.4.3.2.1. CHINA

9.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.3.2.1.2. KEY PLAYERS & KEY PRODUCTS

9.4.3.2.1.3. KEY CONCLUSIONS

9.4.3.2.2. INDIA

9.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.3.2.2.2. KEY PLAYERS & KEY PRODUCTS

9.4.3.2.2.3. KEY CONCLUSIONS

9.4.3.2.3. JAPAN

9.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.3.2.3.2. KEY PLAYERS & KEY PRODUCTS

9.4.3.2.3.3. KEY CONCLUSIONS

9.4.3.2.4. AUSTRALIA

9.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.3.2.4.2. KEY PLAYERS & KEY PRODUCTS

9.4.3.2.4.3. KEY CONCLUSIONS

9.4.3.2.5. REST OF ASIA PACIFIC

9.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.3.2.5.2. KEY PLAYERS & KEY PRODUCTS

9.4.3.2.5.3. KEY CONCLUSIONS

9.4.4. ROW

9.4.4.1. INDUSTRY ANALYSIS 2015-2024 (USD MILLION)

9.4.4.2. TOP COUNTRY ANALYSIS

9.4.4.2.1. LATIN AMERICA

9.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.4.2.1.2. KEY PLAYERS & KEY PRODUCTS

9.4.4.2.1.3. KEY CONCLUSIONS

9.4.4.2.2. MIDDLE EAST & AFRICA

9.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2015-2024 (USD MILLION)

9.4.4.2.2.2. KEY PLAYERS & KEY PRODUCTS

9.4.4.2.2.3. KEY CONCLUSIONS

10. COMPANY PROFILES

10.1. F. HOFFMANN-LA ROCHE AG (SWITZERLAND)

10.1.1. OVERVIEW

10.1.2. PRODUCT PORTFOLIO

10.1.3. STRATEGIC INITIATIVES

10.1.4. SCOT ANALYSIS

10.1.5. STRATEGIC ANALYSIS

10.2. AGILENT TECHNOLOGIES, INC. (U.S.)

10.2.1. OVERVIEW

10.2.2. PRODUCT PORTFOLIO

10.2.3. STRATEGIC INITIATIVES

10.2.4. SCOT ANALYSIS

10.2.5. STRATEGIC ANALYSIS

10.3. QIAGEN N.V. (NETHERLANDS)

10.3.1. OVERVIEW

10.3.2. PRODUCT PORTFOLIO

10.3.3. STRATEGIC INITIATIVES

10.3.4. SCOT ANALYSIS

10.3.5. STRATEGIC ANALYSIS

10.4. THERMO FISHER SCIENTIFIC INC. (U.S.)

10.4.1. OVERVIEW

10.4.2. PRODUCT PORTFOLIO

10.4.3. STRATEGIC INITIATIVES

10.4.4. SCOT ANALYSIS

10.4.5. STRATEGIC ANALYSIS

10.5. ABBOTT LABORATORIES, INC. (U.S.)

10.5.1. OVERVIEW

10.5.2. PRODUCT PORTFOLIO

10.5.3. STRATEGIC INITIATIVES

10.5.4. SCOT ANALYSIS

10.5.5. STRATEGIC ANALYSIS

10.6. MYRIAD GENETICS, INC. (U.S.)

10.6.1. OVERVIEW

10.6.2. PRODUCT PORTFOLIO

10.6.3. STRATEGIC INITIATIVES

10.6.4. SCOT ANALYSIS

10.6.5. STRATEGIC ANALYSIS

10.7. DANAHER CORPORATION (U.S.)

10.7.1. OVERVIEW

10.7.2. PRODUCT PORTFOLIO

10.7.3. STRATEGIC INITIATIVES

10.7.4. SCOT ANALYSIS

10.7.5. STRATEGIC ANALYSIS

10.8. ALMAC GROUP (U.S.)

10.8.1. OVERVIEW

10.8.2. PRODUCT PORTFOLIO

10.8.3. STRATEGIC INITIATIVES

10.8.4. SCOT ANALYSIS

10.8.5. STRATEGIC ANALYSIS

10.9. SYSMEX CORPORATION (JAPAN)

10.9.1. OVERVIEW

10.9.2. PRODUCT PORTFOLIO

10.9.3. STRATEGIC INITIATIVES

10.9.4. SCOT ANALYSIS

10.9.5. STRATEGIC ANALYSIS

10.10. GENOMIC HEALTH, INC. (U.S.)

10.10.1. OVERVIEW

10.10.2. PRODUCT PORTFOLIO

10.10.3. STRATEGIC INITIATIVES

10.10.4. SCOT ANALYSIS

10.10.5. STRATEGIC ANALYSIS

10.11. GE HEALTHCARE LTD(US)

10.11.1. OVERVIEW

10.11.2. PRODUCT PORTFOLIO

10.11.3. STRATEGIC INITIATIVES

10.11.4. SCOT ANALYSIS

10.11.5. STRATEGIC ANALYSIS

10.12. LIFE TECHNOLOGIES CORPORATION (U.S.)

10.12.1. OVERVIEW

10.12.2. PRODUCT PORTFOLIO

10.12.3. STRATEGIC INITIATIVES

10.12.4. SCOT ANALYSIS

10.12.5. STRATEGIC ANALYSIS

10.13. DANAHER CORPORATION (U.S.)

10.13.1. OVERVIEW

10.13.2. PRODUCT PORTFOLIO

10.13.3. STRATEGIC INITIATIVES

10.13.4. SCOT ANALYSIS

10.13.5. STRATEGIC ANALYSIS

10.14. ILLUMINA, INC (U.S.)

10.14.1. OVERVIEW

10.14.2. PRODUCT PORTFOLIO

10.14.3. STRATEGIC INITIATIVES

10.14.4. SCOT ANALYSIS

10.14.5. STRATEGIC ANALYSIS

10.15. ARUP LABORATORIES INC (U.S.)

10.15.1. OVERVIEW

10.15.2. PRODUCT PORTFOLIO

10.15.3. STRATEGIC INITIATIVES

10.15.4. SCOT ANALYSIS

10.15.5. STRATEGIC ANALYSIS

LIST OF TABLES

1. GLOBAL COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2015-2023 (USD MILLION)

2. GLOBAL ASSAY KITS AND REAGENTS MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

3. GLOBAL SOFTWARE AND SERVICES MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

4. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

5. GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

6. GLOBAL IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

7. GLOBAL NEXT GENERATION SEQUENCING MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

8. GLOBAL POLYMERASE CHAIN REACTION MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

9. GLOBAL OTHER TECHNOLOGIES MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

10. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

11. GLOBAL ONCOLOGY MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

12. GLOBAL NEUROLOGY MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

13. GLOBAL INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

14. GLOBAL OTHER INDICATIONS MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

15. GLOBAL COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

16. GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

17. GLOBAL REFERENCE LABORATORIES MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

18. GLOBAL OTHER END USER MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

19. NORTH AMERICA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

20. EUROPE COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

21. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

22. REST OF THE COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

23. NORTH AMERICA COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2015-2024 (USD MILLION)

24. NORTH AMERICA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

25. NORTH AMERICA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

26. NORTH AMERICA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

27. EUROPE COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2015-2024 (USD MILLION)

28. EUROPE COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

29. EUROPE COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

30. EUROPE COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

31. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2015-2024 (USD MILLION)

32. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

33. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

34. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

35. ROW COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2015-2024 (USD MILLION)

36. ROW COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

37. ROW COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

38. ROW COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

39. UNITED STATES COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

40. UNITED STATES COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

41. UNITED STATES COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

42. CANADA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

43. CANADA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

44. CANADA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

45. UK COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

46. UK COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

47. UK COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

48. GERMANY COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

49. GERMANY COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

50. GERMANY COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

51. FRANCE COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

52. FRANCE COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

53. FRANCE COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

54. SPAIN COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

55. SPAIN COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

56. SPAIN COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

57. ROE COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

58. ROE COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

59. ROE COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

60. CHINA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

61. CHINA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

62. CHINA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

63. INDIA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

64. INDIA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

65. INDIA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

66. JAPAN COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

67. JAPAN COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

68. JAPAN COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

69. AUSTRALIA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

70. AUSTRALIA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

71. AUSTRALIA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

72. ROAPAC COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

73. ROAPAC COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

74. ROAPAC COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

75. LATIN AMERICA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

76. LATIN AMERICA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

77. LATIN AMERICA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

78. MENA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

79. MENA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

80. MENA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

LIST OF FIGURES

1. GLOBAL COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

2. GLOBAL ASSAY KITS AND REAGENTS MARKET 2015-2024 (USD MILLION)

3. GLOBAL IN SITU HYBRIDIZATION MARKET 2015-2024 (USD MILLION)

4. GLOBAL IN SITU HYBRIDIZATION MARKET 2015-2024 (USD MILLION)

5. GLOBAL POLYMERASE CHAIN REACTION MARKET 2015-2024 (USD MILLION)

6. GLOBAL IMMUNOHISTOCHEMISTRY MARKET 2015-2024 (USD MILLION)

7. GLOBAL NEXT GENERATION SEQUENCING MARKET 2015-2024 (USD MILLION)

8. GLOBAL OTHER TECHNOLOGIES GLOBAL ONCOLOGY MARKET 2015-2024 (USD MILLION)

9. GLOBAL ONCOLOGY MARKET 2015-2024 (USD MILLION)

10. GLOBAL NEUROLOGY MARKET Y 2015-2024 (USD MILLION)

11. GLOBAL INFECTIOUS DISEASES MARKET 2015-2024 (USD MILLION)

12. GLOBAL OTHER INDICATIONS MARKET 2015-2024 (USD MILLION)

13. GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET 2015-2024 (USD MILLION)

14. GLOBAL REFERENCE LABORATORIES MARKET 2015-2024 (USD MILLION)

15. GLOBAL OTHER END USER MARKET 2015-2024 (USD MILLION)

16. UNITED STATES (U.S.) COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

17. CANADA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

18. UNITED KINGDOM (UK) COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

19. FRANCE COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

20. GERMANY COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

21. RUSSIA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

22. ROE COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

23. INDIA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

24. CHINA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

25. JAPAN COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

26. AUSTRALIA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

27. ROAPAC COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

28. LATIN AMERICA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

29. MENA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

1. GLOBAL COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

2. GLOBAL ASSAY KITS AND REAGENTS MARKET 2015-2024 (USD MILLION)

3. GLOBAL IN SITU HYBRIDIZATION MARKET 2015-2024 (USD MILLION)

4. GLOBAL IN SITU HYBRIDIZATION MARKET 2015-2024 (USD MILLION)

5. GLOBAL POLYMERASE CHAIN REACTION MARKET 2015-2024 (USD MILLION)

6. GLOBAL IMMUNOHISTOCHEMISTRY MARKET 2015-2024 (USD MILLION)

7. GLOBAL NEXT GENERATION SEQUENCING MARKET 2015-2024 (USD MILLION)

8. GLOBAL OTHER TECHNOLOGIES GLOBAL ONCOLOGY MARKET 2015-2024 (USD MILLION)

9. GLOBAL ONCOLOGY MARKET 2015-2024 (USD MILLION)

10. GLOBAL NEUROLOGY MARKET Y 2015-2024 (USD MILLION)

11. GLOBAL INFECTIOUS DISEASES MARKET 2015-2024 (USD MILLION)

12. GLOBAL OTHER INDICATIONS MARKET 2015-2024 (USD MILLION)

13. GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET 2015-2024 (USD MILLION)

14. GLOBAL REFERENCE LABORATORIES MARKET 2015-2024 (USD MILLION)

15. GLOBAL OTHER END USER MARKET 2015-2024 (USD MILLION)

16. UNITED STATES (U.S.) COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

17. CANADA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

18. UNITED KINGDOM (UK) COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

19. FRANCE COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

20. GERMANY COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

21. RUSSIA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

22. ROE COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

23. INDIA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

24. CHINA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

25. JAPAN COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

26. AUSTRALIA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

27. ROAPAC COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

28. LATIN AMERICA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

29. MENA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

1. GLOBAL COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2015-2023 (USD MILLION)

2. GLOBAL ASSAY KITS AND REAGENTS MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

3. GLOBAL SOFTWARE AND SERVICES MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

4. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

5. GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

6. GLOBAL IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

7. GLOBAL NEXT GENERATION SEQUENCING MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

8. GLOBAL POLYMERASE CHAIN REACTION MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

9. GLOBAL OTHER TECHNOLOGIES MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

10. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

11. GLOBAL ONCOLOGY MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

12. GLOBAL NEUROLOGY MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

13. GLOBAL INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

14. GLOBAL OTHER INDICATIONS MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

15. GLOBAL COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

16. GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

17. GLOBAL REFERENCE LABORATORIES MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

18. GLOBAL OTHER END USER MARKET BY GEOGRAPHY 2015-2024 (USD MILLION)

19. NORTH AMERICA COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

20. EUROPE COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

21. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

22. REST OF THE COMPANION DIAGNOSTIC MARKET 2015-2024 (USD MILLION)

23. NORTH AMERICA COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2015-2024 (USD MILLION)

24. NORTH AMERICA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

25. NORTH AMERICA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

26. NORTH AMERICA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

27. EUROPE COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2015-2024 (USD MILLION)

28. EUROPE COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

29. EUROPE COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

30. EUROPE COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

31. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2015-2024 (USD MILLION)

32. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

33. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

34. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

35. ROW COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2015-2024 (USD MILLION)

36. ROW COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

37. ROW COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

38. ROW COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

39. UNITED STATES COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

40. UNITED STATES COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

41. UNITED STATES COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

42. CANADA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

43. CANADA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

44. CANADA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

45. UK COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

46. UK COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

47. UK COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

48. GERMANY COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

49. GERMANY COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

50. GERMANY COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

51. FRANCE COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

52. FRANCE COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

53. FRANCE COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

54. SPAIN COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

55. SPAIN COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

56. SPAIN COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

57. ROE COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

58. ROE COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

59. ROE COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

60. CHINA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

61. CHINA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

62. CHINA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

63. INDIA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

64. INDIA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

65. INDIA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

66. JAPAN COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

67. JAPAN COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

68. JAPAN COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

69. AUSTRALIA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

70. AUSTRALIA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

71. AUSTRALIA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

72. ROAPAC COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

73. ROAPAC COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

74. ROAPAC COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

75. LATIN AMERICA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

76. LATIN AMERICA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

77. LATIN AMERICA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

78. MENA COMPANION DIAGNOSTIC MARKET BY INDICATION 2015-2024 (USD MILLION)

79. MENA COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2015-2024 (USD MILLION)

80. MENA COMPANION DIAGNOSTIC MARKET, BY END USER 2015-2024 (USD MILLION)

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

10.1. F. HOFFMANN-LA ROCHE AG (SWITZERLAND)

10.1.1. OVERVIEW

10.1.2. PRODUCT PORTFOLIO

10.1.3. STRATEGIC INITIATIVES

10.1.4. SCOT ANALYSIS

10.1.5. STRATEGIC ANALYSIS

10.2. AGILENT TECHNOLOGIES, INC. (U.S.)

10.2.1. OVERVIEW

10.2.2. PRODUCT PORTFOLIO

10.2.3. STRATEGIC INITIATIVES

10.2.4. SCOT ANALYSIS

10.2.5. STRATEGIC ANALYSIS

10.3. QIAGEN N.V. (NETHERLANDS)

10.3.1. OVERVIEW

10.3.2. PRODUCT PORTFOLIO

10.3.3. STRATEGIC INITIATIVES

10.3.4. SCOT ANALYSIS

10.3.5. STRATEGIC ANALYSIS

10.4. THERMO FISHER SCIENTIFIC INC. (U.S.)

10.4.1. OVERVIEW

10.4.2. PRODUCT PORTFOLIO

10.4.3. STRATEGIC INITIATIVES

10.4.4. SCOT ANALYSIS

10.4.5. STRATEGIC ANALYSIS

10.5. ABBOTT LABORATORIES, INC. (U.S.)

10.5.1. OVERVIEW

10.5.2. PRODUCT PORTFOLIO

10.5.3. STRATEGIC INITIATIVES

10.5.4. SCOT ANALYSIS

10.5.5. STRATEGIC ANALYSIS

10.6. MYRIAD GENETICS, INC. (U.S.)

10.6.1. OVERVIEW

10.6.2. PRODUCT PORTFOLIO

10.6.3. STRATEGIC INITIATIVES

10.6.4. SCOT ANALYSIS

10.6.5. STRATEGIC ANALYSIS

10.7. DANAHER CORPORATION (U.S.)

10.7.1. OVERVIEW

10.7.2. PRODUCT PORTFOLIO

10.7.3. STRATEGIC INITIATIVES

10.7.4. SCOT ANALYSIS

10.7.5. STRATEGIC ANALYSIS

10.8. ALMAC GROUP (U.S.)

10.8.1. OVERVIEW

10.8.2. PRODUCT PORTFOLIO

10.8.3. STRATEGIC INITIATIVES

10.8.4. SCOT ANALYSIS

10.8.5. STRATEGIC ANALYSIS

10.9. SYSMEX CORPORATION (JAPAN)

10.9.1. OVERVIEW

10.9.2. PRODUCT PORTFOLIO

10.9.3. STRATEGIC INITIATIVES

10.9.4. SCOT ANALYSIS

10.9.5. STRATEGIC ANALYSIS

10.10. GENOMIC HEALTH, INC. (U.S.)

10.10.1. OVERVIEW

10.10.2. PRODUCT PORTFOLIO

10.10.3. STRATEGIC INITIATIVES

10.10.4. SCOT ANALYSIS

10.10.5. STRATEGIC ANALYSIS

10.11. GE HEALTHCARE LTD(US)

10.11.1. OVERVIEW

10.11.2. PRODUCT PORTFOLIO

10.11.3. STRATEGIC INITIATIVES

10.11.4. SCOT ANALYSIS

10.11.5. STRATEGIC ANALYSIS

10.12. LIFE TECHNOLOGIES CORPORATION (U.S.)

10.12.1. OVERVIEW

10.12.2. PRODUCT PORTFOLIO

10.12.3. STRATEGIC INITIATIVES

10.12.4. SCOT ANALYSIS

10.12.5. STRATEGIC ANALYSIS

10.13. DANAHER CORPORATION (U.S.)

10.13.1. OVERVIEW

10.13.2. PRODUCT PORTFOLIO

10.13.3. STRATEGIC INITIATIVES

10.13.4. SCOT ANALYSIS

10.13.5. STRATEGIC ANALYSIS

10.14. ILLUMINA, INC (U.S.)

10.14.1. OVERVIEW

10.14.2. PRODUCT PORTFOLIO

10.14.3. STRATEGIC INITIATIVES

10.14.4. SCOT ANALYSIS

10.14.5. STRATEGIC ANALYSIS

10.15. ARUP LABORATORIES INC (U.S.)

10.15.1. OVERVIEW

10.15.2. PRODUCT PORTFOLIO

10.15.3. STRATEGIC INITIATIVES

10.15.4. SCOT ANALYSIS

10.15.5. STRATEGIC ANALYSIS

Companion diagnostics market, market research report, market share, market analysis, market trends, market forecast 2017-2024

select a license
Single User License
USD 5000 INR 345000
Corporate User License
USD 7000 INR 483000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com